转移性结直肠癌的治疗:ASCO指南
ASCO召集专家小组对相关研究进行系统评价,制定了转移性结直肠癌(mCRC)的治疗推荐。推荐涉及双药或三药化疗联合抗VEGF抗体、基于MMR状态和肿瘤部位的免疫治疗或靶向治疗、BRAF V600E突变后线治疗、腹膜转移的手术与HIPEC、寡转移的SBRT及肝转移的围手术期化疗等。
要点
- 初治不可切除mCRC可提供双药化疗或三药化疗联合抗VEGF抗体。
- MSI-H/dMMR一线推荐帕博利珠单抗;MSS/pMMR左半RAS野生型推荐化疗联合抗EGFR,右半推荐化疗联合抗VEGF。
- 既往治疗进展的BRAF V600E突变mCRC推荐恩考芬尼联合西妥昔单抗。
核心结论
- ASCO专家小组基于系统评价制定了mCRC治疗的推荐意见。
研究设计与样本
- ASCO召集专家小组进行系统评价并制定临床实践推荐,共纳入5项系统评价和10项随机对照试验。
主要发现
- 初治不可切除mCRC可提供双药化疗或三药化疗,依据为化疗联合抗血管内皮生长因子(VEGF)抗体的研究。
- MSI-H或dMMR肿瘤一线推荐帕博利珠单抗。
- MSS或pMMR左半RAS野生型初治mCRC推荐化疗联合抗表皮生长因子受体(EGFR)治疗。
- MSS或pMMR右半RAS野生型mCRC推荐化疗联合抗VEGF治疗。
- 既往至少一线治疗进展的BRAF V600E突变mCRC推荐恩考芬尼联合西妥昔单抗。
关键数值与推荐
- 细胞减灭术联合全身化疗可推荐用于部分结直肠腹膜转移患者,但不推荐加用腹腔热灌注化疗(HIPEC)。
- 全身治疗后,不可切除的肝寡转移患者可推荐立体定向体部放疗(SBRT)。
- 不常规推荐选择性内放射治疗用于单叶或多叶肝转移患者。
- 适合潜在治愈性肝转移切除的mCRC患者应提供围手术期化疗或单纯手术。
- 推荐多学科团队管理和共享决策。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop recommendations for treatment of patients with metastatic colorectal cancer (mCRC). METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS: Five systematic reviews and 10 randomized controlled trials met the systematic review inclusion criteria. RECOMMENDATIONS: Doublet chemotherapy should be offered, or triplet therapy may be offered to patients with previously untreated, initially unresectable mCRC, on the basis of included studies of chemotherapy in combination with anti-vascular endothelial growth factor antibodies. In the first-line setting, pembrolizumab is recommended for patients with mCRC and microsatellite instability-high or deficient mismatch repair tumors; chemotherapy and anti-epidermal growth factor receptor therapy is recommended for microsatellite stable or proficient mismatch repair left-sided treatment-naive RAS wild-type mCRC; chemotherapy and anti-vascular endothelial growth factor therapy is recommended for microsatellite stable or proficient mismatch repair RAS wild-type right-sided mCRC. Encorafenib plus cetuximab is recommended for patients with previously treated BRAF V600E-mutant mCRC that has progressed after at least one previous line of therapy. Cytoreductive surgery plus systemic chemotherapy may be recommended for selected patients with colorectal peritoneal metastases; however, the addition of hyperthermic intraperitoneal chemotherapy is not recommended. Stereotactic body radiation therapy may be recommended following systemic therapy for patients with oligometastases of the liver who are not considered candidates for resection. Selective internal radiation therapy is not routinely recommended for patients with unilobar or bilobar metastases of the liver. Perioperative chemotherapy or surgery alone should be offered to patients with mCRC who are candidates for potentially curative resection of liver metastases. Multidisciplinary team management and shared decision making are recommended. Qualifying statements with further details related to implementation of guideline recommendations are also included.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
引用
- Morris VK, Kennedy EB, Baxter NN, et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol. 2022. PMID: 36252154. doi:10.1200/JCO.22.01690
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。